At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Rare Disease Report sat down with Ruben Mesa, MD of the Mayo Clinic to discuss myelofibrosis pathophysiology, supportive care - like yoga and exercise - for patients, and his study evaluating the combination of ruxolitinib and momelotinib.
Among the questions asked were:
Describe the current treatment of thrombocytosis patients who are intolerant or resistant to hydroxyurea? (0:01)
Describe the phase 2 study involving ruxolitinib with azacytidine to treat myelofibrosis. (2:09)
Are any other studies currently being conducted with the combination of ruxolitinib and azacytidine? (3:41)
Can you provide an overview of the pathophysiology and treatment of thrombocytosis? (5:09)
Can you also speak to the pathophysiology and treatment of myelofibrosis? (6:23)